Martin W. Mackay, Ph.D., is co-founder, former Chief Executive Officer (2018-2023), former Executive Chair (2023-2024), and current Non-Executive Chair of Rallybio Corporation. From May 2013 to June 2017, Dr. Mackay served as the Global Head of Research & Development at Alexion Pharmaceuticals, Inc., and from July 2010 to January 2013 he served as President of R&D at AstraZeneca PLC, where he led the research and development organization and had overall accountability for delivering new products from its pipeline.
Dr. Mackay previously served on the boards of Novo Nordisk and SpringWorks Therapeutics, and from October 2020 through April 2022 served as a director of 5:01 Acquisition Corp. He has been a director of Charles River since July 2017 and serves as Lead Independent Director; in connection with the January 2026 leadership transition plan, he is expected to become Chair of the Board effective May 5, 2026. Dr. Mackay's extensive experience leading research and development organizations at both global pharmaceutical and biotechnology companies provides the Company with a unique combination of expertise.